{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:58:17Z","timestamp":1761058697169},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.1007\/s11864-002-0013-4","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T08:42:22Z","timestamp":1183020142000},"page":"235-245","source":"Crossref","is-referenced-by-count":8,"title":["Newly diagnosed multiple myeloma"],"prefix":"10.1007","volume":"3","author":[{"given":"Donna M.","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,28]]},"reference":[{"key":"13_CR1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1365-2141.1997.1122939.x","volume":"97","author":"DM Weber","year":"1997","unstructured":"Weber DM, Dimopoulos MA, Moulopoulos LA, et al.: Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997, 97:810\u2013814.","journal-title":"Br J Haematol"},{"key":"13_CR2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","volume":"50","author":"M Hjorth","year":"1993","unstructured":"Hjorth M, Hellquist L, Holmberg E, et al.: Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: a randomized study. Eur J Hematol 1993, 50:95\u2013102.","journal-title":"Eur J Hematol"},{"key":"13_CR3","first-page":"20","volume":"32","author":"R Alexanian","year":"1995","unstructured":"Alexanian R, Dimopoulos MA: Management of multiple myeloma. Semin Hematol 1995, 32:20\u201330.","journal-title":"Semin Hematol"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V96.2.754","volume":"96","author":"S Dudeny","year":"2000","unstructured":"Dudeny S, Hussein MA, Karam MA, et al.: Kyphoplasty (KPT) in the treatment of vertebral compression fractures due to multiple myeloma (MM). Blood 2000, 96:754. Abstract #3290.","journal-title":"Blood"},{"key":"13_CR5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Parker L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced myeloma. N Engl J Med 1996, 334:488\u2013493.","journal-title":"N Engl J Med"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0037-1963(01)90090-3","volume":"38","author":"JR Berenson","year":"2001","unstructured":"Berenson JR: New advances in the biology and treatment of myeloma bone disease. Semin Hematol 2001, 38:15\u201320.","journal-title":"Semin Hematol"},{"key":"13_CR7","doi-asserted-by":"crossref","unstructured":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists\u2019 Collaborative Group. J Clin Oncol 1998, 16:3832-3842.","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.1990.tb02564.x","volume":"74","author":"M Hjorth","year":"1998","unstructured":"Hjorth M, Hellquist L, Holmberg E, et al.: Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. Br J Haematol 1998, 74:185\u2013191.","journal-title":"Br J Haematol"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2141.1997.d01-2041.x","volume":"96","author":"M Boccadoro","year":"1997","unstructured":"Boccadoro M, Palumbo A, Argentino C, et al.: Conventional induction treatments do not influence overall survival in multiple myeloma. Br J Haematol 1997, 96:333\u2013337.","journal-title":"Br J Haematol"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.1991.9.3.444","volume":"9","author":"M Boccadoro","year":"1991","unstructured":"Boccadoro M, Marmont F, Tribalto M, et al.: Multiple myeloma: VMCP\/VBAP alternating combination: chemotherapy is not superior to melphalan and prednisone even in high risk patients. J Clin Oncol 1991, 9:444\u2013448.","journal-title":"J Clin Oncol"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","volume":"80","author":"R Alexanian","year":"1992","unstructured":"Alexanian R, Dimopoulos MA, DeLasalle K, et al.: Primary dexamethasone treatment of multiple myeloma. Blood 1992, 80:887\u2013890.","journal-title":"Blood"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","volume":"33","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990, 33:86\u201389.","journal-title":"Am J Hematol"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb05114.x","volume":"88","author":"MA Dimopoulos","year":"1994","unstructured":"Dimopoulos MA, Palumbo A, DeLasalle K, et al.: Primary plasma cell leukemia. Br J Haematol 1994, 88:754\u2013759.","journal-title":"Br J Haematol"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0889-8588(18)30350-2","volume":"6","author":"M Boccadoro","year":"1992","unstructured":"Boccadoro M, Pileri A: Standard chemotherapy for myelomatosis: an area of great controversy. Hematol Clin North Am 1992, 6:371\u2013382.","journal-title":"Hematol Clin North Am"},{"key":"13_CR15","doi-asserted-by":"crossref","unstructured":"Interferon-_2b added to melphalan-prednisone for initial maintenance therapy in multiple myeloma. The Nordic Myeloma Study Group.} Ann Intern Med 1996, 124:212-222.","DOI":"10.7326\/0003-4819-124-2-199601150-00004"},{"key":"13_CR16","doi-asserted-by":"crossref","unstructured":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. The Myeloma Trialists\u2019 Collaborative Group. Br J Haematol 2001, 113:1020-1034.","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"key":"13_CR17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-124-2-199601150-00012","volume":"124","author":"R Alexanian","year":"1996","unstructured":"Alexanian R, Weber D: Whither interferon for multiple myeloma and other hematologic malignancies: Ann Intern Med 1996, 124:264\u2013265.","journal-title":"Ann Intern Med"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1998.16.3.890","volume":"16","author":"SE Salmon","year":"1998","unstructured":"Salmon SE, Crowley JJ, Batcerzak SP, et al.: Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1998, 16:890\u2013896.","journal-title":"J Clin Oncol"},{"key":"13_CR19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H","volume":"65","author":"R Alexanian","year":"2000","unstructured":"Alexanian R, Weber D, Dimopoulos M, et al.: Randomized trial of _-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol 2000, 65:204\u2013209.","journal-title":"Am J Hematol"},{"key":"13_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau J, Stoppa J, et al.: Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. N Engl J Med 1996, 335:91\u201397.","journal-title":"N Engl J Med"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S, et al.: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92:3131\u20133136.","journal-title":"Blood"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V84.12.4278.bloodjournal84124278","volume":"84","author":"R Alexanian","year":"1994","unstructured":"Alexanian R, Dimopoulos MA, Hester J, et al.: Early myeloablative therapy for multiple myeloma. Blood 1994, 84:4276\u20134282.","journal-title":"Blood"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/stem.5530130718","volume":"13","author":"R Alexanian","year":"1995","unstructured":"Alexanian R, Dimopoulos MA, DeLasalle KB, et al.: Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995, 13:118\u2013121.","journal-title":"Stem Cells"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/sj.bmt.1703035","volume":"27","author":"R Alexanian","year":"2001","unstructured":"Alexanian R, Weber D, Giralt S, et al.: Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001, 27:1037\u20131043.","journal-title":"Bone Marrow Transplant"},{"key":"13_CR25","first-page":"850a","volume":"98","author":"R Alexanian","year":"2001","unstructured":"Alexanian R, Weber DM, Delasalle KB: Frequency and impact of complete remission in patients with multiple myeloma of low tumor mass who received intensive therapy supported by autologous stem cell transplantation (IT + ASCT). Blood 2001, 98:850a. Abstract #3530.","journal-title":"Blood"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"D Siegel","year":"1999","unstructured":"Siegel D, Desikan KR, Mehta J, et al.: Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999, 93:51\u201354.","journal-title":"Blood"},{"key":"13_CR27","unstructured":"Attal M, Harrousseau JL, Facon T: Single versus double transplant in myeloma: a randomized trial of the \"Inter Groupe Francais Du Myelome (IFM). VIII International Myeloma Workshop, Banff, Alberta, Canada; May 4\u20138, 2001."},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93:55\u201365.","journal-title":"Blood"},{"key":"13_CR29","first-page":"849a","volume":"98","author":"SV Rajkumar","year":"2001","unstructured":"Rajkumar SV, Hayman SR, Gertz MA, et al.: Combination therapy with thalidomide plus dexamethasone THAL\/DEX) for newly diagnosed myeloma (mm). Blood 2001, 98:849a. Abstract #3525.","journal-title":"Blood"},{"key":"13_CR30","unstructured":"Weber DM, Rankin K, Delasalle K, et al.: Thalidomide alone and in combination for previously untreated myeloma. VIII International Myeloma Workshop, Banff, Alberta, Canada; May 4\u20138, 2001."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-002-0013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-002-0013-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-002-0013-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T19:17:00Z","timestamp":1587669420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-002-0013-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s11864-002-0013-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}